Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Finally Nabs Meda In Diversification Play

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal coincides with full year/fourth quarter earnings release.

You may also be interested in...



Deal Watch: Mylan Counts On A Renaissance For Expansion

European markets are the name of the game as Ariad sells its European business to Incyte, Spain's Grupo Ferrer buys out Alexza, Italy's Chiesi bags a suite of CV drugs from The Medicines Co. and Swiss kidney disease specialist Vifor Fresenius takes up Opko's Rayaldee.

Deal Watch: AbbVie Moves Into Microbiome, Synthetic Biology With Synlogic Partnership

Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.

Pharma's Love Affair With Dealmaking: No End In Sight

The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS079093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel